

Integration of SIR-Spheres® Y-90 resin microspheres in your mCRC clinical practice

1st Line

The SIRFLOX protocol: In 1st line treatment of patients with non-resectable CRC liver metastases, the addition of SIRT to FOLFOX based chemotherapy significantly extended median liver PFS.¹

1st Line Consolidation or Maintenance

- Integrate SIR-Spheres Y-90 resin microspheres as maintenance or for consolidation during 1st line treatment²
- When patients can no longer tolerate intensive therapy
- For patients who are good candidates for a chemo holiday

2nd or 3rd Line

- Add SIR-Spheres Y-90 resin microspheres to your existing 2nd line regimen to extend patient tumor control³
- Use SIR-Spheres Y-90 resin microspheres in patients with limited options i.e. RAS mutant, who will not benefit from EGFR inhibitors⁴

Salvage

- Use SIR-Spheres Y-90 resin microspheres as a tolerable and effective palliative treatment in patients who have failed standard first and second line therapies, before multi-kinase inhibitors which may increase bilirubin and thus prohibit further treatment⁴

Ideal Patient Characteristics

- Non-resectable liver-only or liver-dominant metastatic disease
- Liver tumor involvement <60%
- ECOG performance scale of 0 – 2
- Remaining chemotherapy options

References:

1. Gibbs P *et al.* 2015 ASCO Annual Meeting; *J Clin Oncol* 2015;**33** (Suppl): Abs 3502.
2. Fakih M *Colorect Cancer* 2014;**3** (4) 331-343.
3. van Hazel G *et al.* *J Clin Oncol* 2009;**27**: 4089-4095.
4. Hendlisz A *et al.* *J Clin Oncol* 2010;**28**: 3687-3694.



Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. SIR-Spheres Y-90 resin microspheres may only be distributed to a duly licensed or accredited facility capable of handling therapeutic medical isotopes. This product is radioactive and should thus be handled in accordance with all applicable standards and regulations. **Intended Use / Indications For Use:** SIR-Spheres Y-90 resin microspheres are approved for use in Argentina, Australia, Brazil, the European Union (CE Mark), Switzerland, Turkey, and several countries in Asia for the treatment of unresectable liver tumors. In the US, SIR-Spheres Y-90 resin microspheres have a Pre-Market Approval (PMA) from the FDA and are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Fluoruridine). **Warnings / Precautions:** Inadvertent delivery of the microspheres to locations other than the intended hepatic tumor may result in local radiation damage. Due to the radioactivity and the significant consequences of misplacing the microspheres in situ, this product must be implanted by physicians who have completed the Sirtex TEC training program. A SPECT scan of the upper abdomen immediately after implantation is recommended. Patients may experience abdominal pain immediately after administration and pain relief may be required. H-2 blocking agents may be administered the day before implantation and continued as needed to reduce gastric complications. **Side Effects:** Common side effects are fever, transient decrease of hemoglobin, mild to moderate abnormality of liver function tests, abdominal pain, nausea, vomiting, and diarrhea. Potential serious effects due to exposure to high radiation include acute pancreatitis, radiation pneumonitis, acute gastritis, radiation hepatitis, and acute cholecystitis. **Contraindications:** SIR-Spheres Y-90 resin microspheres should not be implanted in patients who have either had previous external beam radiation therapy to the liver, ascites, or are in clinical liver failure. This device is contraindicated in patients with markedly abnormal synthetic and excretory liver function tests, greater than 20% lung shunting of the hepatic artery blood flow, disseminated extra-hepatic malignant disease, and portal vein thrombosis. This device should not be implanted in patients determined via angiogram to have an abnormal vascular anatomy that would result in significant reflux of the hepatic arterial blood flow to the stomach, pancreas or bowel. **Reference the Package Insert (www.sirtex.com) for a complete listing of indications, contraindications, side effects, warnings, and precautions.**